dexamethasone + infliximab

The combination of dexamethasone and infliximab represents a dual therapeutic approach that has been studied for its effects on inflammatory conditions. This combination therapy involves two distinct medications with different mechanisms of action that can work together to modulate inflammatory responses. Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory properties, while infliximab is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key cytokine involved in inflammatory processes. When used together, these medications can provide complementary effects in managing certain inflammatory conditions. According to research, this combination has been studied for its ability to attenuate the ductular reaction in liver injury models, showing potential in modulating the adaptive remodeling of biliary architecture that occurs upon liver injury and can limit extracellular matrix deposition.